Header Logo

Connection

NANCY WEIGEL to Male

Back to Details
This is a "connection" page, showing publications NANCY WEIGEL has written about Male.
NANCY WEIGEL
Connection Strength
0.520
Male
  1. Cistrome and transcriptome analysis identifies unique androgen receptor (AR) and AR-V7 splice variant chromatin binding and transcriptional activities. Sci Rep. 2022 03 30; 12(1):5351.
    View in: PubMed
    Score: 0.029
  2. Isoform-specific Activities of Androgen Receptor and its Splice Variants in Prostate Cancer Cells. Endocrinology. 2021 03 01; 162(3).
    View in: PubMed
    Score: 0.027
  3. Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells. Sci Rep. 2021 01 14; 11(1):1393.
    View in: PubMed
    Score: 0.027
  4. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. Oncotarget. 2017 Jul 04; 8(27):44447-44464.
    View in: PubMed
    Score: 0.021
  5. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget. 2015 Oct 13; 6(31):31997-2012.
    View in: PubMed
    Score: 0.019
  6. Hormones and Cancer--Looking Forward. Horm Cancer. 2015 Dec; 6(5-6):189-90.
    View in: PubMed
    Score: 0.019
  7. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol. 2014 Sep; 54:49-59.
    View in: PubMed
    Score: 0.017
  8. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. Endocrinology. 2014 Sep; 155(9):3262-73.
    View in: PubMed
    Score: 0.017
  9. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013 Dec; 140(3):223-38.
    View in: PubMed
    Score: 0.016
  10. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol. 2013 Apr; 45(4):763-72.
    View in: PubMed
    Score: 0.016
  11. 1a,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest. Prostate. 2011 Jan 01; 71(1):98-110.
    View in: PubMed
    Score: 0.014
  12. Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug; 74(8):669-74.
    View in: PubMed
    Score: 0.012
  13. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology. 2009 May; 150(5):2046-54.
    View in: PubMed
    Score: 0.012
  14. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol. 2008 Nov; 22(11):2420-32.
    View in: PubMed
    Score: 0.012
  15. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol. 2008; 617:245-55.
    View in: PubMed
    Score: 0.011
  16. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr Rev. 2007 Aug; 65(8 Pt 2):S116-7.
    View in: PubMed
    Score: 0.011
  17. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006 Nov 01; 66(21):10594-602.
    View in: PubMed
    Score: 0.010
  18. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem. 2006 Oct 01; 99(2):362-72.
    View in: PubMed
    Score: 0.010
  19. Identification of CAND1 as a DNA-dependent protein kinase-regulated coactivator of androgen receptor and the ARv7 splice variant. PLoS One. 2026; 21(5):e0349130.
    View in: PubMed
    Score: 0.010
  20. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005 Sep 01; 64(4):362-72.
    View in: PubMed
    Score: 0.009
  21. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005 Sep 01; 65(17):7959-67.
    View in: PubMed
    Score: 0.009
  22. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol. 2005 Oct; 97(1-2):37-46.
    View in: PubMed
    Score: 0.009
  23. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate. 2005 Jun 15; 64(1):9-19.
    View in: PubMed
    Score: 0.009
  24. Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089). Bone. 2004 Jul; 35(1):134-43.
    View in: PubMed
    Score: 0.009
  25. 1alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate. 2004 May 15; 59(3):282-91.
    View in: PubMed
    Score: 0.009
  26. Vitamin D and prostate cancer. Exp Biol Med (Maywood). 2004 Apr; 229(4):277-84.
    View in: PubMed
    Score: 0.008
  27. Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3. Prostate. 2003 Sep 01; 56(4):293-304.
    View in: PubMed
    Score: 0.008
  28. Repressors of androgen and progesterone receptor action. J Biol Chem. 2003 Aug 15; 278(33):31136-48.
    View in: PubMed
    Score: 0.008
  29. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology. 2003 Jan; 144(1):50-60.
    View in: PubMed
    Score: 0.008
  30. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol. 2002 Dec; 16(12):2692-705.
    View in: PubMed
    Score: 0.008
  31. Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients. Cells. 2022 07 29; 11(15).
    View in: PubMed
    Score: 0.008
  32. Vitamin D and prostate cancer. J Androl. 2002 Jan-Feb; 23(1):9-17.
    View in: PubMed
    Score: 0.007
  33. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 2000 Feb 15; 60(4):779-82.
    View in: PubMed
    Score: 0.006
  34. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology. 2000 Jan; 141(1):10-7.
    View in: PubMed
    Score: 0.006
  35. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) Mol Endocrinol. 1999 Dec; 13(12):2065-75.
    View in: PubMed
    Score: 0.006
  36. Vitamin D and prostate cancer. Proc Soc Exp Biol Med. 1999 Jun; 221(2):89-98.
    View in: PubMed
    Score: 0.006
  37. Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. Oncogene. 2019 02; 38(7):1121-1135.
    View in: PubMed
    Score: 0.006
  38. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Cancer Res. 2018 07 15; 78(14):4022-4035.
    View in: PubMed
    Score: 0.006
  39. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018 05; 73(5):715-723.
    View in: PubMed
    Score: 0.005
  40. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 1997 Apr; 138(4):1491-7.
    View in: PubMed
    Score: 0.005
  41. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem. 1996 Aug 16; 271(33):19900-7.
    View in: PubMed
    Score: 0.005
  42. Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun. 2016 05 19; 7:11612.
    View in: PubMed
    Score: 0.005
  43. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 08 01; 22(15):3937-49.
    View in: PubMed
    Score: 0.005
  44. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18261-6.
    View in: PubMed
    Score: 0.004
  45. Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res. 2014 Feb 07; 13(2):1088-100.
    View in: PubMed
    Score: 0.004
  46. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol. 2013 Jan; 42(1):35-43.
    View in: PubMed
    Score: 0.004
  47. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 2011 Jan 15; 71(2):572-82.
    View in: PubMed
    Score: 0.003
  48. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther. 2009 Jul; 8(7):1787-98.
    View in: PubMed
    Score: 0.003
  49. Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res. 2009 Jul; 7(7):1119-31.
    View in: PubMed
    Score: 0.003
  50. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids. 2006 Feb; 71(2):102-15.
    View in: PubMed
    Score: 0.002
  51. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res. 2004 Dec 01; 10(23):8018-27.
    View in: PubMed
    Score: 0.002
  52. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol. 2003 Apr; 169(4):1553-7.
    View in: PubMed
    Score: 0.002
  53. Molecular analysis of the androgen receptor in ten prostate cancer specimens obtained before and after androgen ablation. J Androl. 2003 Mar-Apr; 24(2):215-25.
    View in: PubMed
    Score: 0.002
  54. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate. 2001 Nov 01; 49(3):224-33.
    View in: PubMed
    Score: 0.002
  55. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst. 2001 Sep 05; 93(17):1314-24.
    View in: PubMed
    Score: 0.002
  56. Androgen receptors and their biology. Vitam Horm. 2001; 62:199-230.
    View in: PubMed
    Score: 0.002
  57. Androgen receptor mutations in prostate cancer. Cancer Res. 2000 Feb 15; 60(4):944-9.
    View in: PubMed
    Score: 0.002
  58. 7alpha-Iodo and 7alpha-fluoro steroids as androgen receptor-mediated imaging agents. J Med Chem. 1999 Jun 03; 42(11):2021-34.
    View in: PubMed
    Score: 0.002
  59. An alternative ligand-independent pathway for activation of steroid receptors. Recent Prog Horm Res. 1995; 50:333-47.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.